Article Text

Download PDFPDF

Cost-effectiveness of interventions to control cardiovascular diseases and type 2 diabetes mellitus in South Asia: protocol for a systematic review
  1. Kavita Singh1,
  2. Ambalam M Chandra Sekaran2,
  3. Soumyadeep Bhaumik3,
  4. Malini Aisola4,
  5. Kaushik Chattopadhyay5,
  6. Anuji U Gamage6,
  7. Padmal de Silva7,
  8. Sakthivel Selvaraj4,
  9. Ambuj Roy1,
  10. Dorairaj Prabhakaran2,4,
  11. Nikhil Tandon1
  1. 1All India Institute of Medical Sciences, New Delhi, India
  2. 2Centre for Chronic Disease Control, Gurgaon, Haryana, India
  3. 3BioMedical Genomics Centre, Kolkata, India
  4. 4Public Health Foundation of India, Institute for Studies in Industrial Development Campus, New Delhi, India
  5. 5London School of Hygiene and Tropical Medicine, London, UK
  6. 6Nutrition Division, Ministry of Health, Colombo, Sri Lanka
  7. 7Department of Research, WHO Collaborating Centre on Public Health Workforce Development, National Institute of Health Sciences, Kalutara, Sri Lanka
  1. Correspondence to Kavita Singh; kavita{at}ccdcindia.org

Abstract

Introduction While a number of strategies are being implemented to control cardiovascular diseases (CVDs) and type 2 diabetes mellitus (T2DM), the cost-effectiveness of these in the South Asian context has not been systematically evaluated. We aim to systematically review the economic (cost-effectiveness) evidence available on the individual-, group- and population-level interventions for control of CVD and T2DM in South Asia.

Methods and analysis This review will consider all relevant economic evaluations, either conducted alongside randomised controlled trials or based on decision modelling estimates. These studies must include participants at risk of developing CVD/T2DM or with established disease in one or more of the South Asian countries (India, Bangladesh, Pakistan, Sri Lanka, Nepal, Maldives, Bhutan and Afghanistan). We will identify relevant papers by systematically searching all major databases and registries. Selected articles will be screened by two independent researchers. Methodological quality of the studies will be assessed using a modified Drummond and a Phillips checklist. Cochrane guidelines will be followed for bias assessment in the effectiveness studies.

Results Results will be presented in line with the PRISMA (Preferred Reporting Items for Systematic review and Meta-analysis) checklist, and overall quality of evidence will be presented as per the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach.

Ethics and dissemination The study has received ethics approval from the All India Institute of Medical Sciences, New Delhi, India. The results of this review will provide policy-relevant recommendations for the uptake of cost-effectiveness evidence in prioritising decisions on essential chronic disease care packages for South Asia.

Study registration number PROSPERO CRD42013006479.

  • Economic evaluations
  • cardiovascular diseases
  • type 2 diabetes mellitus
  • south asia

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.